Zongertinib (LuciZonger) 60mg | Laos Generic HER2 Inhibitor for NSCLC | GLT

REQUEST A QUOTE

Tap "Request a Quote" to open WhatsApp — the product details are already filled in. Just add your quantity and destination country.

  • We reply within 24 hours with pricing, availability & COA
  • Serves individuals and institutions worldwide

Prefer email? [email protected] · +86 15234153837

Share
Product description

Generic Information: LuciZonger (Zongertinib) — Laos Generic Version

LuciZonger is a licensed generic version of zongertinib, the first-in-class oral HER2 tyrosine kinase inhibitor originally developed by Boehringer Ingelheim. It is manufactured by Lucius Pharmaceuticals in Laos and is registered in that country under marketing authorization number 12 L 1427/26. LuciZonger is supplied as 60 mg × 60 tablets per bottle, matching the originator's most common pack size.

For patients and institutions looking for a more affordable way to access zongertinib, LuciZonger offers the same active ingredient as the originator at a fraction of the cost. It has become a popular, budget-friendly alternative for those who cannot comfortably afford the Western or Chinese originator list prices, while still being a formally registered and traceable product from an established Lao pharmaceutical manufacturer.

What Is LuciZonger?

LuciZonger is an oral tablet form of zongertinib produced as a generic medicine. Each tablet contains 60 mg of zongertinib, and each bottle holds 60 tablets — a standard one-month supply for a patient on the 120 mg daily dose. As a generic, it contains the same active pharmaceutical ingredient as Hernexeos and is intended to be therapeutically equivalent, offering patients a lower-cost route to the same targeted therapy.

How Does LuciZonger (Zongertinib) Work?

Like the originator, LuciZonger works by blocking the HER2 (ERBB2) tyrosine kinase domain. In NSCLC tumours that depend on HER2 activating mutations for their growth, this blockade interrupts the signalling that drives cancer cell proliferation and survival. The result is targeted anti-tumour activity against the HER2-mutant clone. Because zongertinib is taken orally once a day, LuciZonger fits naturally into a long-term outpatient treatment routine.

Indications

LuciZonger is used for the same indication as originator zongertinib: adult patients with unresectable or metastatic non-squamous non-small cell lung cancer whose tumours have a HER2 (ERBB2) tyrosine kinase domain activating mutation. It is intended for patients who have already received prior systemic therapy and whose disease has progressed. As always, HER2 mutation testing must confirm the diagnosis before this medicine is appropriate.

Dosage

The dosing of LuciZonger follows the same weight-based schedule as the originator. Patients under 90 kg take 120 mg (two tablets) once daily, and patients at or above 90 kg take 180 mg (three tablets) once daily. One 60 mg × 60 tablet bottle lasts about one month for lighter patients and roughly three weeks for heavier patients. Dose adjustments for tolerability should always be directed by the treating oncologist.

Side Effects

Common side effects reported with zongertinib include diarrhoea, rash, stomatitis, fatigue, reduced appetite, and elevated liver enzymes. Some patients may develop nausea or anaemia. These effects are typically manageable and often improve with supportive measures or dose modification. Regular monitoring of liver function and overall health is advised, and any concerning symptoms should be reported to the prescribing doctor without delay.

Storage

Keep LuciZonger tablets in their original bottle at room temperature, protected from heat, moisture, and direct sunlight. Ensure the cap is tightly closed and store the medicine where children cannot reach it. Do not use tablets past the expiry date on the packaging, and retain the batch information for your records.

Why Choose LuciZonger?

LuciZonger is the budget-conscious choice for zongertinib therapy. It provides the same 60 mg strength and the same convenient 60-tablet pack as the originator, but at a cost that is several times lower than the China-Mainland originator and dramatically lower than the United States list price. For a patient weighing under 90 kg, a single bottle can cover a full month of treatment at a price that makes long-term therapy far more sustainable. Choosing a registered Lao generic from Lucius Pharmaceuticals is a practical way to obtain genuine zongertinib without paying originator premiums.

How to Order LuciZonger (Zongertinib Generic)

To order LuciZonger, reach out to GLT using the contact details below. Please have a valid prescription and documentation of HER2 mutation status ready. We can provide information on current availability, sourcing from Laos, and shipping arrangements for individual patients and bulk institutional orders.

WhatsApp: +86 15234153837  |  Email: [email protected]

FAQ

Is LuciZonger the same as Hernexeos? LuciZonger contains the same active ingredient, zongertinib, as Hernexeos, but it is a generic produced by Lucius Pharmaceuticals in Laos rather than the originator brand from Boehringer Ingelheim. Both are supplied as 60 mg × 60 tablets.

How much does generic zongertinib cost? LuciZonger is priced several times lower than the China-Mainland originator and far below the United States list price, making it the most economical option for many patients. Contact us for a current quotation.

Is LuciZonger legally registered? Yes, LuciZonger is a registered generic in Laos under authorization number 12 L 1427/26, produced by Lucius Pharmaceuticals.

What is the dose of LuciZonger? The dose is 120 mg once daily for patients under 90 kg and 180 mg once daily for patients 90 kg or more, taken as 60 mg tablets.

Can I buy zongertinib generic online? Yes, generic zongertinib (LuciZonger) can be ordered through GLT. A valid prescription and HER2 mutation confirmation are required before ordering.

Related Oncology Products

Selpercatinib (Sepadx) 40mg — RET-Driven Cancer | GLT

Generic selpercatinib (Bigbear) for RET-driven lung and thyroid cancer

Sotoxen (Sotorasib) 120mg*56's | Generic KRAS G12C Inhibitor | Everest Pharmaceuticals Ltd. | GLT

Generic sotorasib (KRAS G12C inhibitor) by Everest Pharmaceuticals Ltd. (Bangladesh) — an affordable alternative to...

Zongertinib (Hernexeos) 60mg | China-Sourced HER2 Inhibitor for NSCLC | GLT

NMPA-approved originator zongertinib for HER2-mutant NSCLC, 60mg × 60 tablets.

Lumakras (Sotorasib) 120mg Tablets | KRAS G12C NSCLC & mCRC | Amgen US | GLT

Amgen's first-in-class KRAS G12C inhibitor, FDA-approved for KRAS G12C-mutated NSCLC and mCRC.

Sotakras (Sotorasib) 120mg*56's | Generic KRAS G12C Inhibitor | Ziska Pharmaceuticals Ltd. | GLT

Generic sotorasib (KRAS G12C inhibitor) by Ziska Pharmaceuticals Ltd. (Bangladesh) — an affordable alternative to...

Zongertinib (LuciZonger) 60mg | Laos Generic HER2 Inhibitor for NSCLC | GLT

Registered Laos generic zongertinib for HER2-mutant NSCLC, 60mg × 60 tablets.

Selpercatinib (Selcaxen) 40mg — RET-Driven Cancer | GLT

Affordable generic selpercatinib (Everest) for RET-driven lung and thyroid cancer

Osimitib (Osimertinib) 80mg*30 | Laos Alliance Generic | GLT

Laos Alliance Pharmaceutical Group — registered osimertinib 80mg generic (03 L 0953/23)